Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement.
Across FY2007–FY2025: $11.87B in buybacks, $2.82B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
We are party to a $1.5 billion five-year unsecured credit facility that will expire on June 7, 2028, pursuant to which we are permitted to establish an incremental revolving credit facility of up to $750 million. We also entered into an Uncommitted Money Market Line Credit agreement which provides for an aggregate borrowing capacity of $300 million. Under our U.S. commercial paper program, the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.5 billion with up to 397-day maturities. As of January 31, 2026, we had approximately $3.4 billion in outstanding indebtedness which included an aggregate outstanding principal amount of $3.3 billion in unsecured senior notes. We may borrow additional amounts in the future and use the proceeds from any future borrowing for general corporate purposes, future acquisitions, expansion of our business or repurchases of our outstanding shares of common stock.
We are party to a $1.5 billion five-year unsecured credit facility that will expire on June 7, 2028, pursuant to which we are permitted to establish an incremental revolving credit facility of up to $750 million. We also entered into an Uncommitted Money Market Line Credit agreement which provides for an aggregate borrowing capacity of $300 million. Under our U.S. commercial paper program, the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.5 billion with up to 397-day maturities. As of October 31, 2025, we had approximately $3.4 billion in outstanding indebtedness which included an aggregate outstanding principal amount of $3.3 billion in unsecured senior notes. We may borrow additional amounts in the future and use the proceeds from any future borrowing for general corporate purposes, future acquisitions, expansion of our business or repurchases of our outstanding shares of common stock.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
5 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
4 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
4.900% Senior Notes due 2032
Note · Agilent Technologies, Inc.
Reference: 4.900% Senior Notes due 2032
Active
Original principal
USD 600,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—
Last reported interest terms:
4.9%
Reported 2026-06-25Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
This Registration Rights Agreement (this “Agreement”), dated June 25, 2026, is entered into by and among Agilent Technologies, Inc., a Delaware corporation (the “Company”), and Citigroup Global Markets Inc., Mizuho Securities USA LLC and SG Americas Securities, LLC (collectively with, for and on behalf of the Initial Purchasers named in the Purchase Agreement referred to below, the “Initial Purchasers”). The Company proposes to issue and sell to the Initial Purchasers, upon the terms set forth in a purchase agreement, dated June 22, 2026 (the “Purchase Agreement”), $600,000,000 principal amount of its 4.900% Senior Notes due 2032 (the “Original Notes”) (such sale, the “Initial Placement”). As an inducement to the Initial Purchasers to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the holders from time to time of the Registrable Securities (as defined below), including you (each of the foregoing a “Holder” and together the “Holders”), as follows:
Issuer evidence: This Registration Rights Agreement (this “Agreement”), dated June 25, 2026, is entered into by and among Agilent Technologies, Inc., a Delaware corporation (the “Company”), and Citigroup Global Markets Inc., Mizuho Securities USA LLC and SG Americas Securities, LLC (collectively with, for and on behalf of the Initial Purchasers named in the Purchase Agreement referred to below, the “Initial Purchasers”). The Company proposes to issue and sell to the Initial Purchasers, upon the terms set forth in a purchase agreement, dated June 22, 2026 (the “Purchase Agreement”), $600,000,000 principal amount of its 4.900% Senior Notes due 2032 (the “Original Notes”) (such sale, the “Initial Placement”). As an inducement to the Initial Purchasers to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the holders from time to time of the Registrable Securities (as defined below), including you (each of the foregoing a “Holder” and together the “Holders”), as follows:
Supporting evidence: This Registration Rights Agreement (this “Agreement”), dated June 25, 2026, is entered into by and among Agilent Technologies, Inc., a Delaware corporation (the “Company”), and Citigroup Global Markets Inc., Mizuho Securities USA LLC and SG Americas Securities, LLC (collectively with, for and on behalf of the Initial Purchasers named in the Purchase Agreement referred to below, the “Initial Purchasers”). The Company proposes to issue and sell to the Initial Purchasers, upon the terms set forth in a purchase agreement, dated June 22, 2026 (the “Purchase Agreement”), $600,000,000 principal amount of its 4.900% Senior Notes due 2032 (the “Original Notes”) (such sale, the “Initial Placement”). As an inducement to the Initial Purchasers to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the holders from time to time of the Registrable Securities (as defined below), including you (each of the foregoing a “Holder” and together the “Holders”), as follows:
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.86×
Peer median 6.25×
EV/EBIT
30.88×
Peer median 35.33×
P/E (TTM)
33.80×
Peer median 36.60×
Peer medians compare against the 19 similar-size Diagnostics & Research companies (of 50 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Agilent CrossLab
$2,908,000,000
$2,747,000,000
$2,656,000,000
$1,452,000,000
$1,360,000,000
$1,177,000,000
$1,840,000,000
$1,701,000,000
Life Sciences and Diagnostics Markets
$2,726,000,000
$2,466,000,000
$2,780,000,000
—
—
—
—
—
Applied Markets
$1,314,000,000
$1,297,000,000
$1,397,000,000
—
—
—
—
—
Diagnostics and Genomics
—
$1,651,000,000
$1,755,000,000
$1,766,000,000
$1,296,000,000
$1,047,000,000
$1,021,000,000
$943,000,000
Life Sciences and Applied Markets
—
$3,215,000,000
$3,510,000,000
$3,630,000,000
$3,663,000,000
$3,115,000,000
$2,302,000,000
$2,270,000,000
By Geography (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Rest of World
$3,382,000,000
$3,047,000,000
$3,040,000,000
$2,964,000,000
$2,887,000,000
$2,500,000,000
$2,525,000,000
$2,485,000,000
United States
$2,342,000,000
$2,246,000,000
$2,410,000,000
$2,385,000,000
$2,159,000,000
$1,752,000,000
$1,619,000,000
$1,414,000,000
China
$1,224,000,000
$1,217,000,000
$1,383,000,000
$1,499,000,000
$1,273,000,000
$1,087,000,000
$1,019,000,000
$1,015,000,000
By Product & Service (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Non Instrumentationand Other
$4,521,000,000
$4,156,000,000
$4,091,000,000
$3,941,000,000
$3,662,000,000
$3,090,000,000
$3,013,000,000
—
Instrumentation
$2,427,000,000
$2,354,000,000
$2,742,000,000
$2,907,000,000
$2,657,000,000
$2,249,000,000
$2,150,000,000
—
Product
—
—
—
—
—
—
—
$3,746,000,000
Service Other
—
—
—
—
—
—
—
$1,168,000,000
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
